Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF APRIL 05, 2012 FBO #3785
SOURCES SOUGHT

A -- Assessment of Potential Cocaine Treatment Medications

Notice Date
4/3/2012
 
Notice Type
Sources Sought
 
NAICS
541712 — Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
 
ZIP Code
20892
 
Solicitation Number
N01DA-13-8908
 
Archive Date
5/5/2012
 
Point of Contact
Lisa V. Bielen, Phone: 301.443.6677
 
E-Mail Address
lisa.bielen@nih.gov
(lisa.bielen@nih.gov)
 
Small Business Set-Aside
N/A
 
Description
The purpose of this research and development contract is the preclinical evaluation of test compounds as potential pharmacotherapies for substance abuse. To this end, the offeror and technical personnel need to have the capability and experience to conduct experiments evaluating compounds in the mouse locomotor activity, rat drug discrimination, rat conditioned place preference, mouse stress-induced potentiation of conditioned place preference, and rat self-administration paradigms. The offeror and technical staff also need to have experience conducting these types of experiments using cocaine, methamphetamine, nicotine, THC, and hallucinogens. Evidence of experience must be documented through publications using the relevant behavioral models listed above. In addition, the offeror needs to have the dedicated laboratory space, animal care facilities, and equipment required to conduct these behavioral assays. Proprietary compounds will be evaluated using established protocols, and the resulting data will be utilized by the Addiction Treatment Discovery Program of the NIDA Division of Pharmacotherapies and Medical Consequences of Drug Abuse. The successful offeror must submit documentation of a current DEA registration for Schedules II - IV controlled substances and the eligibility to obtain Schedule I prior to award. All offerors must be in compliance with the NIH guidelines on the care and use of laboratory animals. Offerors should demonstrate capability to administer and coordinate interrelated tasks in an effective and timely manner.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/N01DA-13-8908/listing.html)
 
Record
SN02712992-W 20120405/120403235945-5cdc25e7570ddfce900cf7a29c8c33d9 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.